B-cell chronic lymphocytic leukemia is the commonest form of leukemia in the Western world, characterized by an accumulation of monoclonal CD5 þ B cells in the peripheral blood and lymphoid organs. It is clinically a heterogenous disease with overall variable response to many drugs used either alone or in combination, and is currently untreatable. Rituximab has been successfully applied in the clinic in combination with Fludarabine, or Fludarabine and Dexamethasone, and Mitoxantrone. 1, 2 We sought to investigate the mechanisms of Rituximab-induced apoptosis in chronic lymphocytic leukemia cells through the upregulation of AU-rich binding proteins that can target certain mRNAs for degradation. 3, 4 We found that 20 mg/ml of Rituximab induced apoptosis when crosslinked with an anti-human Fcg-specific antibody (referred to as XRituximab), especially at 48 h post-stimulation as measured by either propidium iodide alone or Annexin V-propidium iodide methods, which is in agreement with earlier work. 5 Using the Annexin V-propidium iodide method, it was found that the cell viability of the untreated cells at 24 h was 81% and was significantly reduced to 69.9% (Pp0.05, n ¼ 10) by XRituximab whereas Rituximab alone did not have any significant effect ( Figure 1a ). Using the same method at 48 h, it was found that cell viability was decreased from 84% in untreated cells to 51% (Pp0.001, n ¼ 8) by XRituximab whereas Rituximab alone again minimally affected cell viability ( Figure 1a) . Levels of apoptosis of cells incubated with the anti-human Fcg-specific secondary antibody alone were not statistically different from levels of apoptosis in cells incubated in medium alone (Figure 1a) .
When we measured the expression of Tis11 family, consisting of Tis11, Tis11b and Tis11d, by northern blot, we found that expression of only Tis11b was significantly upregulated by XRituximab at 3 h post-stimulation whereas the expression of Tis11d remained unchanged and the expression of Tis11 remained unchanged or was weakly downregulated (Figures  1b-d) . Then we attempted to correlate levels of induction of Tis11b mRNA with response to XRituximab and found that, with the exception of patients with high White Blood Count, the fold induction of Tis11b mRNA correlated well with the efficiency of XRituximab in inducing apoptosis (Table 1) . In order to further quantify the fold increase in Tis11b mRNA following treatment with XRituximab, we used quantitative real-time PCR, which was applied in a total of five patients. This method showed that the relative to b-actin fold induction in Tis11b mRNA following XRituximab treatment was 3.5 ± 0.6 (mean ± s.e.m.) at 3 h poststimulation (Figure 1e) . Then we measured possible induction of Tis11b protein by western blot using a rabbit polyclonal antiTis11b antibody. It was found that XRituximab clearly induced Tis11b protein at 3 h post-stimulation and this induction remained above basal levels of expression for up to 24 h poststimulation (Figure 1f ). In fact, at 3 h post-stimulation more than one band was detected, with corresponding size at around 36 kDa, indicating probably multiple phosphorylated forms of Tis11b induced by XRituximab. Interestingly, two of these bands disappeared at 24 h post-stimulation (Figure 2a ). These data are consistent with earlier published work showing that Tis11 bears multiple phosphorylation sites that can be targeted by pathways such as p38, JNK, ERK and is actually phosphorylated in certain cell types. 6, 7 It should be mentioned that phosphorylation probably inhibits Tis11 family function as mRNA degradationcausing proteins, 6 and our results may explain why induction of apoptosis in chronic lymphocytic leukemia shows slow kinetics if indeed Tis11b is indispensable for this effect.
Induction of Tis11b protein was also verified through intracellular staining and FACS analysis to somehow quantify the percentage of cells that responded to XRituximab treatment in terms of Tis11b protein induction. This method showed that Tis11b protein was induced in 50-80% of the cells at 3 h poststimulation in different patients tested, reflecting possibly differences in CD20 expression and efficiency in crosslinking of Rituximab between different patients, or differences at the genetic level involved in the regulation of Tis11b among different patients (Figure 1f ). When confocal microscopy analysis was performed, it showed that Tis11b is exclusively localized in the cytoplasm with a diffuse rather than punctuate pattern of staining (data not shown). Cytoplasm is the site where mRNA degradation occurs.
When we used inhibitors specific for certain pathways, namely p38 (SB203580), JNK (SP600125) and ERK (U0126), we found that only p38 inhibition reduced the efficiency of XRituximab-induced apoptosis (Supplementary Figure 1a) , which is in agreement with published data. 5 Interestingly, this inhibitor was the only one that abolished Tis11b mRNA (Supplementary Figure 1b) and protein (Supplementary Figure  1c) induction by XRituximab, suggesting a direct functional role for Tis11b in inducing apoptosis by XRituximab.
Therefore, for functional studies on Tis11b, we used small interfering RNA (siRNA), which was transfected into chronic lymphocytic leukemia cells using either Lipofectamine 2000 (Invitrogen, Paisley, UK) or HiPerFect (QIAGEN, Crawley, UK). The cells were transfected and preincubated for 48 h before they were stimulated with XRituximab and further incubated for 24 h after the addition of the monoclonal antibody. Transfection of Bcell chronic lymphocytic leukemia cells with siRNA typically resulted in 50-65% transfection efficiency (data not shown). Analytically when Lipofectamine 2000 was used, we found that XRituximab increased the percentage of apoptotic cells from 19.0±5.7% (mean±s.e.m.) in untreated cells to 38.0±4.0%, but only to 30 ± 4.20% in the presence of Tis11b siRNA. The presence of a non-silencing siRNA (negative control) minimally affected the efficiency of XRituximab in inducing apoptosis (37±2.5%) (Pp0.16) (Figure 2a ). When HiPerFect was used, we found that the percentage of apoptosis for untreated B-cell chronic lymphocytic leukemia cells was 30% and was increased to 48% by XRituximab (Pp0.001) but in the presence of Tis11b siRNA this was limited to only 33.5±4.6% (Pp0.05, n ¼ 7) (Figure 2b) . The presence of a nonsilencing siRNA (negative control) again minimally affected the efficiency of XRituximab in inducing apoptosis (43.7 ± 3.7%). The siRNA for Tis11b used in this study efficiently downregulated Tis11b mRNA (by more than 90%) as measured by quantitative real-time PCR (Figure 2c ) and Tis11b protein as measured by intracellular staining and FACS analysis (Figure 2d ). According to the latter method, Tis11b was induced in 52% of the cells in the absence of siRNA but only in 27% in the presence of Tis11b siRNA, which corresponds to 45% downregulation at the protein level. (Figure 3a) . However, XRituximab was always more efficient than Rituximab in inducing apoptosis, and Rituximab alone did not reach statistical significance even at 48 h post-stimulation (Figure 3a) . Induction of apoptosis was accompanied by induction of Tis11b mRNA at 3 h (Figure 3b ), but with no significant change in Tis11 and Tis11d (data not shown). Finally, Tis11b protein was transfected by electroporation into Ramos cells to verify the induction of apoptosis by this protein in the absence of a drug, using a Tis11b-containing vector (pIRES-EGFP-Tis11b). At 48 h post-transfection, the levels of Annexin-positive cells were similar (approximately 4%) for untransfected and empty-vector (IRES2-EGFP)-transfected cells, whereas ectopic expression of Tis11b Letters to the Editor increased this percentage to 12.6% (Po0.05) (Figure 3c ). Similarly, at 72 h post-transfection, the percentage of Annexin-positive cells in IRES2-EGFP-transfected cell lines remained low (approx. 4%), but levels were significantly increased to 25.5% (Po0.001) by the exogenously introduced Tis11b protein (Figure 3c ).
Letters to the Editor
In conclusion, this study showed a clear induction of Tis11b mRNA and protein in chronic lymphocytic leukemia cells treated with Rituximab in vitro, and, more importantly, that this protein directly mediates the pro-apoptotic effects of this monoclonal antibody, as shown by siRNA technology. As microarray studies have also shown induction of Tis11b in response to Rituximab treatment in a B-non-Hodgkin's lymphoma cell line (DHL4), 8 these data suggest a drug-specific induction of this gene in several B-cell malignancies that can be treated with Rituximab. Possible targets of Tis11b in mediating its function may include Bcl-2, XIAP, c-IAP2 and TNF-a, all bearing the UUAUUUAUU canonical sequence in their 3 0 -UTR, which is considered a molecular target of the Tis11 family members. Further work is necessary to establish which genes are being targeted by Tis11b in response to Rituximab treatment and is currently in progress in our lab.
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